These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19806595)

  • 1. Many unknowns in low-risk prostate cancer treatment. Ongoing studies and biomarker research may shed light on best approach.
    Printz C
    Cancer; 2009 Oct; 115(20):4645-6. PubMed ID: 19806595
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of prostate specific antigen. A review].
    Brasso K; Skaarup P; Roosen JU; Iverson P
    Ugeskr Laeger; 1998 Jul; 160(31):4510-6. PubMed ID: 9700305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 4. Testing for prostate cancer. A consumer view.
    Gardner M
    Aust Fam Physician; 2003 Jun; 32(6):398-9. PubMed ID: 12833762
    [No Abstract]   [Full Text] [Related]  

  • 5. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
    Lin DW
    Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the diagnosis of prostate cancer in high-risk men: the supplementary biomarker approach.
    Kommu S; Persad R; Watkin N; Boyd PJ; Eeles R
    BJU Int; 2005 Jan; 95(1):5-7. PubMed ID: 15638884
    [No Abstract]   [Full Text] [Related]  

  • 7. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 8. Legal implications of prostate cancer: what you should know.
    Reeves JD; Schellhammer PF
    Va Med Q; 1993; 120(2):77-9. PubMed ID: 7683209
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient education. PSA: pros and cons.
    Gattellari M; Ward JE
    Aust Fam Physician; 2003 Jun; 32(6):429-30. PubMed ID: 12833769
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjunct assays for improving prostate cancer detection.
    Bahnson R
    J Urol; 2009 Sep; 182(3):825. PubMed ID: 19616258
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 12. Integrative tumor board: recently diagnosed prostate cancer.
    Schacht MJ; Saxe GA; Bauer-Wu S; Kennedy S; Monti DA; Peterson C; Rosenberg Z; Block KI
    Integr Cancer Ther; 2003 Mar; 2(1):63-90. PubMed ID: 12941168
    [No Abstract]   [Full Text] [Related]  

  • 13. [Markers of prostatic carcinoma].
    Safarík L
    Cas Lek Cesk; 1998 Aug; 137(17):525-7. PubMed ID: 9787505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CE: early localized prostate cancer.
    Katz A
    Am J Nurs; 2015 Mar; 115(3):34-44; quiz 45-6. PubMed ID: 25674683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and prognostic markers in prostate cancer. A study of cell-cycle regulators, angiogenesis and candidate markers.
    Halvorsen OJ
    APMIS Suppl; 2008; (123):5-62. PubMed ID: 18771090
    [No Abstract]   [Full Text] [Related]  

  • 16. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of free prostate specific antigen (fPSA) on a nanoporous gold platform.
    Shulga OV; Zhou D; Demchenko AV; Stine KJ
    Analyst; 2008 Mar; 133(3):319-22. PubMed ID: 18299744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA: prostate-specific antigen, persisting scientific ambiguities.
    Harv Mens Health Watch; 2009 Jul; 13(12):1-6. PubMed ID: 19718841
    [No Abstract]   [Full Text] [Related]  

  • 19. Trouble in the waterworks: a view from the inside.
    Thomison JB
    J Tenn Med Assoc; 1993 Mar; 86(3):125-6. PubMed ID: 7680395
    [No Abstract]   [Full Text] [Related]  

  • 20. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development.
    Schalken JA
    Eur Urol; 2010 Jul; 58(1):19-20. PubMed ID: 20227175
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.